MedTrace Logo

Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

NCT03398668 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-03-13

No results posted yet for this study

Summary

This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).

Conditions

Interventions

DEVICE

Relievion device- Treatment stimulation

1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation

DEVICE

Relievion Device- Sham stimulation

1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation

Sponsors & Collaborators

  • Neurolief Ltd.

    lead INDUSTRY

Principal Investigators

  • Daniel Dr. Oved, Dr. · Laniado Medical center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2018-12-30
Completion
2018-12-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03398668 on ClinicalTrials.gov